-+ 0.00%
-+ 0.00%
-+ 0.00%

NEUPHORIA THERAPEUTICS INC - AFFIRM-1 PHASE 3 TRIAL OF BNC-210 TOPLINE READOUT EXPECTED Q3 2025 - SEC FILING

Reuters·05/20/2025 20:17:47

Please log in to view news